Polarity Transduction Enables the Formal Electronically Mismatched Radical Addition to Alkenes
作者:Subhasis Paul、Dario Filippini、Mattia Silvi
DOI:10.1021/jacs.2c12699
日期:2023.2.8
The formation of carbon–carbon bonds via the intermolecular addition of alkyl radicals to alkenes is a cornerstone of organic chemistry and plays a central role in synthesis. However, unless specific electrophilic radicals are involved, polarity matching requirements restrict the alkene component to be electron deficient. This limits the scope of a fundamentally important carbon–carbon bond forming
Asymmetric Synthesis of α-Alkylproline Derivatives from a Chiral Borane−Amine Adduct: Inversion of Enantioselectivity in the Presence of a Crown Ether
作者:Vincent Ferey、Patrick Vedrenne、Loïc Toupet、Thierry Le Gall、Charles Mioskowski
DOI:10.1021/jo961432o
日期:1996.1.1
Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P 1 ′ group
作者:Philippe G Nantermet、James C Barrow、Stacey R Lindsley、MaryBeth Young、Shi-Shan Mao、Steven Carroll、Carolyn Bailey、Michele Bosserman、Dennis Colussi、Daniel R McMasters、Joseph P Vacca、Harold G Selnick
DOI:10.1016/j.bmcl.2004.02.033
日期:2004.5
Structural modifications of the aminopyridine P'(1), group of imidazole acetic acid based TAFla inhibitors led to the discovery of the aminocyclopentyl analog 28, a 1 nM TAFla inhibitor with CLT50 functional activity of 14 nM but without selectivity against CPB. While not as active, aminobutyl derivative 27 provided an improved 6.7-fold selectivity for TAFla versus CPB. (C) 2004 Elsevier Ltd. All rights reserved.
Potent small molecule CCR1 antagonists
作者:John C Kath、William H Brissette、Matthew F Brown、Maryrose Conklyn、Amy P DiRico、Peter Dorff、Ronald P Gladue、Brett M Lillie、Paul D Lira、Erin N Mairs、William H Martin、Eric B McElroy、Molly A McGlynn、Timothy J Paradis、Christopher S Poss、Ingrid A Stock、Laurie A Tylaska、Deye Zheng
DOI:10.1016/j.bmcl.2004.02.021
日期:2004.5
The present manuscript details structure-activity relationship studies of lead structure 1, which led to the discovery of CCR1 antagonists >100-fold more potent than 1. (C) 2004 Elsevier Ltd. All rights reserved.